Acorda Therapeutics
Acorda Therapeutics, Inc. is an American biotechnology company based in Pearl River, New York. The company develops therapies that improve neurological function in people with Parkinson's disease, multiple sclerosis and other neurological disorders. Acorda Therapeutics manufactures and markets the drugs Inbrija (levodopa inhalation powder) and Ampyra (dalfampridine) in the United States.
| Company type | Public |
|---|---|
Traded as | Nasdaq: ACOR |
| Industry | |
| Founded | 1995 |
| Founder | Ron Cohen |
| Headquarters | 420 Saw Mill River Road, Ardsley, New York, U.S. |
Key people | Ron Cohen (CEO) |
| Products | |
| Revenue | US$192.408 million (2019) |
| US$−311.632 million (2019) | |
Net income | US$−272.966 million (2019) |
| Total assets | US$799.718 million (2019) |
| Total equity | US$310.820 million (2019) |
Number of employees | 344 (2020) |
| Website | acorda |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.